JNY Stock Chart & Stats
€0.26
€0.00(0.00%)
At close: 4:00 PM EST
€0.26
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.16 - €0.64
Previous CloseN/A
Volume0.00
Average Volume (3M)16.00
Market Cap
€74.20M
Enterprise Value€750.27
Total Cash (Recent Filing)€503.28M
Total Debt (Recent Filing)€262.67M
Price to Earnings (P/E)―
Beta0.61
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.32
Shares Outstanding416,729,430
10 Day Avg. Volume0
30 Day Avg. Volume16
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)1.68
Price to Sales (P/S)3.39
P/FCF Ratio-11.95
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.09
Revenue Forecast (FY)€34.57M
Bulls Say, Bears Say
Bulls Say
Revenue & Gross Margin RecoveryA sustained 55% top-line rebound and a ~43% gross margin materially improve unit economics for a product-led biotech. Durable revenue growth plus higher gross margin supports scaling manufacturing and commercialization investments, reducing the structural gap to profitability if trends persist.
Improving Cash BurnA large reduction in operating cash outflow signals meaningful progress on cost control or working-capital management. This extends runway, lowers near-term external funding needs, and gives management more time to execute product milestones and commercial traction before raising additional capital.
Manageable LeverageModerate debt (D/E ~0.47) reduces near-term solvency risk and preserves capacity to access debt markets if needed. For a capital-intensive cell-therapy developer, lighter leverage provides financial flexibility to fund R&D and scale manufacturing without immediate creditor pressure.
Bears Say
Deep Persistent LossesExtremely large net losses and negative operating profit indicate the business remains far from break-even. Persistent operating deficits erode shareholder equity, constrain reinvestment capacity, and increase dilution risk if the company must issue equity to fund ongoing development and commercialization.
Negative Cash GenerationContinued negative operating and free cash flow creates structural dependency on external financing. In biotech, repeated capital raises dilute shareholders and can delay programs; reliance on intermittent funding heightens execution risk for clinical and manufacturing scale-up plans.
Eroding Equity BaseMaterial equity erosion from cumulative losses weakens the balance sheet and reduces strategic optionality. A deteriorating capital base can lead to tougher financing terms, potential covenant constraints, and diminished capacity to absorb setbacks during expensive late-stage development.
JW (Cayman) Therapeutics Co. Ltd. News
JNY FAQ
What was JW (Cayman) Therapeutics Co. Ltd.’s price range in the past 12 months?
JW (Cayman) Therapeutics Co. Ltd. lowest stock price was €0.15 and its highest was €0.64 in the past 12 months.
What is JW (Cayman) Therapeutics Co. Ltd.’s market cap?
JW (Cayman) Therapeutics Co. Ltd.’s market cap is €74.20M.
When is JW (Cayman) Therapeutics Co. Ltd.’s upcoming earnings report date?
JW (Cayman) Therapeutics Co. Ltd.’s upcoming earnings report date is Sep 01, 2026 which is in 28 days.
How were JW (Cayman) Therapeutics Co. Ltd.’s earnings last quarter?
JW (Cayman) Therapeutics Co. Ltd. released its earnings results on Mar 26, 2026. The company reported -€0.086 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is JW (Cayman) Therapeutics Co. Ltd. overvalued?
According to Wall Street analysts JW (Cayman) Therapeutics Co. Ltd.’s price is currently Overvalued.
Does JW (Cayman) Therapeutics Co. Ltd. pay dividends?
JW (Cayman) Therapeutics Co. Ltd. does not currently pay dividends.
What is JW (Cayman) Therapeutics Co. Ltd.’s EPS estimate?
JW (Cayman) Therapeutics Co. Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does JW (Cayman) Therapeutics Co. Ltd. have?
JW (Cayman) Therapeutics Co. Ltd. has 416,729,430 shares outstanding.
What happened to JW (Cayman) Therapeutics Co. Ltd.’s price movement after its last earnings report?
JW (Cayman) Therapeutics Co. Ltd. reported an EPS of -€0.086 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.412%.
Which hedge fund is a major shareholder of JW (Cayman) Therapeutics Co. Ltd.?
Currently, no hedge funds are holding shares in DE:JNY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
JW (Cayman) Therapeutics Co. Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
142.55%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-38.53%
Trailing 12-Months
Company Description
JW (Cayman) Therapeutics Co. Ltd.
JW (Cayman) Therapeutics Co. Ltd is a clinical-stage biotechnology company dedicated to the development, manufacture, and commercialization of cell-based immunotherapies. The company primarily targets hematological cancers and solid tumors through treatments that harness the body's own immune cells to combat disease, notably including CAR-T therapies. Its leading therapeutic candidate is Carteyva (relmacabtagene autoleucel), an anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy designed to treat a variety of blood cancers. The company's innovative pipeline also features JWCAR129, an autologous CAR-T therapy for multiple myeloma; JWATM204, a TCR T-cell therapy candidate aimed at hepatocellular carcinoma (HCC); and JWATM203, another autologous T-cell receptor mimic therapy specifically targeting alpha-fetoprotein for HCC. Founded in 2016, JW (Cayman) Therapeutics Co. Ltd is headquartered in Shanghai, People's Republic of China.
Technical Analysis
Alphamab Oncology
―
CARsgen Therapeutics Holdings Ltd.
―
Mabpharm Limited
―
CStone Pharmaceuticals
―
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
―